ZS Pharma has raised $46 million in a private financing offering, to advance development of ZS-9, a crystal form of zirconium silicate, designed to treat patients with kidney and liver disease.
The funding will allow the privately held Fort Worth company to proceed with trials for ZS-9 as it prepares for commercialization of the product.
Alta Partners led the new round of financing, joined by new investors RiverVest Venture Partners, 3×5 Special Opportunity Partners and Salem Partners, and by current investor Devon Park Bioventures.
As part of this financing deal, Robert Alexander, general partner of Alta Partners, and John McKearn, managing partner of RiverVest Venture Partners, will join the ZS Pharma Board of Directors.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity